New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
06:34 EDTKINKindred Biosciences upgraded to Outperform from Market Perform at BMO Capital
BMO Capital upgraded Kindred based on increased expectations for the AtoKin product which recently entered Phase 3. The firm now believes AtoKin will be mover competitive with Apoquel and that it can reach $95M-$100M peak sales by 2020-2023. Price target raised to $30 from $15.
News For KIN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for KIN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use